drugset / Trial / NCT04490590
A Clinical Trial of Chidamide Combined With Etoposide in Relapsed or Refractory NK/T-cell Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
To observe the safety, tolerability and clinical effects of Chidamide Combined With Etoposide in Relapsed or Refractory NK/T-cell Lymphoma.
Timeline
- Start
- 2016-10-01
- Primary completion
- 2020-10-01
- Completion
- 2021-10-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Etoposide | Small molecule | 50 mg | Oral |
| Subject | Tucidinostat | Small molecule | 30 mg | Oral |